WHO obesity guidance SBP warns on slimming drugs

Oct 7

In a live Rio report and package, Anna Karina de Carvalho describes WHO's new child and adolescent obesity guidance, emphasizing family care, dietary and activity changes, specialist supervision and age restrictions for medicines or surgery. Latife Salomão Tyszler describes lifestyle changes as the first approach and medicines after unsuccessful interventions. The reporter says 170 million people aged 5–19 had obesity 'in Brazil'; this geographic attribution is what aired, rather than a verified national figure. The package then revisits an August 2026 Brazilian Society of Pediatrics warning about injectable obesity medicines: medical indications, growth and other adverse risks, pressure over appearance, and avoidance of cosmetic use without proper assessment. Adriane Cardoso stresses specialist and multidisciplinary follow-up. Neither guide establishes that all children should receive medicines.

WHO releases its first guidelines addressing obesity among children and adolescents on October 7. Tedros announces strong recommendations for structured diet, behaviour and physical-activity changes, with guidance also addressing medicines, bariatric surgery and weight-loss devices. He stresses health, functioning and well-being beyond weight loss and wider access to healthy diets and activity. His briefing gives a two-to-eight-percent prevalence rise over 25 years and more than 170 million affected young people; those are his stated figures and timeframe. TV Brasil's October 7 live account adds family/lifestyle care, age-specific medicine/surgery restrictions and Latife Salomão Tyszler's specialist-supervision explanation. Its reporter places the 170-million 5–19 obesity figure 'in Brazil' and dates the prevalence rise from 1990, whereas the retrieved direct WHO statement says globally and over 25 years. The aired discrepancy is retained as source attribution, not endorsed or silently reconciled. The report's August SBP note concerns a separate publication.